Astrazeneca boosted as Covid-19 therapies offset vaccine drop
Astrazeneca Plc raised its outlook for 2022 revenue as sales of its Covid-19 therapies offset a decline in its coronavirus vaccine.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Valneva plunges after Europe slashes Covid-19 vaccine order
For subscribers